Peptide innovator says the drug class is due for a rethink - Pharmaceutical Technology

Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption. Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption. An explosion in the popularity of peptides is fueling a wave of technical innovation and unlicensed supply, with regulators playing catch-up. Credit: PiyaZIrconplus/Shutterstock.com The FDA’s acceptance of several untested peptides for human use has left one drug innovator calling for a greater clarity of understanding around a drug class that is widely known but often poorly understood. Peptides have become some of the most profitable medicines in the…

Source: Pharmaceutical Technology